- Most Recent Funding
- $15 Million on November 13, 2013 / Undisclosed Round
Foresight Biotherapeutics is a clinical-stage drug development company pioneering novel therapies designed to address significant unmet needs in ophthalmology and otolaryngology.
Foresight’s platform Povidone-Iodine (PVP-I) technology represents an important breakthrough in the treatment of ocular and otic inflammation including bacterial, viral and fungal infections. This platform enables PVP-I, a well-characterized broad spectrum antiseptic with no known microbial resistance, to be formulated in combination with a range of anti-inflammatory agents.
Current Team (3)Update
50 West 57th Street
New York, NY 10019